Home » Stocks » APVO

Aptevo Therapeutics Inc. (APVO)

Stock Price: $31.57 USD 0.05 (0.16%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
After-hours: $31.30 -0.27 (-0.86%) Jan 20, 4:43 PM
Market Cap 139.43M
Revenue (ttm) 10.97M
Net Income (ttm) -18.87M
Shares Out 3.23M
EPS (ttm) -5.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $31.57
Previous Close $31.52
Change ($) 0.05
Change (%) 0.16%
Day's Open 31.52
Day's Range 30.69 - 32.23
Day's Volume 55,943
52-Week Range 3.11 - 48.36

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Accesswire - 1 week ago

SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-onco...

Zacks Investment Research - 2 weeks ago

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 1 month ago

Aptevo went up hugely on positive phase 1 data in AML. The company develops bispecific antibodies against cancer.

PRNewsWire - 2 months ago

LUND, Sweden and SEATTLE, Nov. 16, 2020 /PRNewswire/ -- Alligator Bioscience ("Alligator") (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumo...

InvestorPlace - 2 months ago

Aptevo Therapeutics (APVO) news for Wednesday includes APVO stock taking a fall after a strong rally yesterday on clinical trial results. The post Aptevo Therapeutics News: Why APVO Stock Is F...

Pulse2 - 2 months ago

The stock price of Aptevo Therapeutics Inc (NASDAQ: APVO) increased by 78.25% as it went from $6.30 at the close on Monday to $11.23 at the close on Tuesday. This is why it happened.

Forbes - 6 months ago

Markets took off this morning following more good news regarding coronavirus vaccines. Less-than-good earnings are expected for corporations, but it doesn't seem that way when looking at the m...

Other stocks mentioned: BLNK, EFOI, EYES, SGBX
Zacks Investment Research - 6 months ago

Aptevo Therapeutics Inc. (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Zacks Investment Research - 6 months ago

Is (APVO) Outperforming Other Medical Stocks This Year?

PRNewsWire - 7 months ago

SEATTLE and LUND, Sweden, June 10, 2020 /PRNewswire/ -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its p...

Benzinga - 9 months ago

Aptevo Therapeutics Inc (NASDAQ: APVO) shares are trading higher on Tuesday, after the company announced it regained compliance with the NASDAQ listing requirements.

Zacks Investment Research - 9 months ago

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 1 year ago

SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today ...

Seeking Alpha - 1 year ago

Aptevo announced preliminary Q3'19 product revenue for its Hemophilia B drug IXINITY will be about $9M.

GlobeNewsWire - 1 year ago

Reports Record Quarterly IXINITY® Net Revenue and New Patient Conversions  Following Launch of New 3,000 IU Assay

GlobeNewsWire - 1 year ago

New ADAPTIR Candidate APVO603 is a Dual-Agonistic Bispecific Antibody Targeting 4-1BB and OX40

Seeking Alpha - 1 year ago

IXINITY revenue increased for the quarter, which is what I wanted to see.

Seeking Alpha - 1 year ago

Investors might want to pay attention to Aptevo Therapeutics over the next several weeks before the company's Q2 results.

About APVO

Aptevo Therapeutics, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinic... [Read more...]

Industry
Biotechnology
CEO
Marvin L. White
Employees
80
Stock Exchange
NASDAQ
Ticker Symbol
APVO
Full Company Profile

Financial Performance

In 2019, APVO's revenue was $32.42 million, an increase of 40.56% compared to the previous year's $23.07 million. Losses were -$40.45 million, -24.66% less than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for APVO stock is "Buy." The 12-month stock price forecast is 65.67, which is an increase of 108.01% from the latest price.

Price Target
$65.67
(108.01% upside)
Analyst Consensus: Buy